Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study

Clinical Endocrinology

Volumn 86, Issue 5, 2017, Pages 725-730

  Tagliaferri, Valeria ^a   Romualdi, Daniela ^a   Immediata, Valentina ^a   De Cicco, Simona ^a   Di Florio, Christian ^a   Lanzone, Antonio ^a,b   Guido, Maurizio ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b Ente Ecclesiastico Ospedale Generale Regionale F Miulli   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; ESTRADIOL; GLUCOSE; HYDROXYPROGESTERONE; INOSITOL; INSULIN; LUTEINIZING HORMONE; METFORMIN; MUELLERIAN INHIBITING FACTOR; PROLACTIN; SEX HORMONE BINDING GLOBULIN; ANTIDIABETIC AGENT;

ADULT; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HIRSUTISM; HORMONE DETERMINATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESPONSE; INSULIN SENSITIVITY; LIPID ANALYSIS; LUTEINIZING HORMONE BLOOD LEVEL; MEASUREMENT; MENSTRUAL CYCLE; METABOLIC PARAMETERS; MIDDLE AGED; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PELVIC EXAMINATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT WITHDRAWAL; WAIST HIP RATIO; COMPLICATION; OUTCOME ASSESSMENT; POLYCYSTIC OVARY SYNDROME; PROCEDURES; YOUNG ADULT;

ADULT; CROSS-OVER STUDIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; METFORMIN; OBESITY; OUTCOME ASSESSMENT (HEALTH CARE); POLYCYSTIC OVARY SYNDROME; YOUNG ADULT;

EID: 85012932448     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.13304     Document Type: Article

References (35)

1. Morin-Papunen, L.C., Vauhkonen, I., Koivunen, R.M. et al. (2000) Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Human Reproduction, 15, 1266–1274.
2. McCartney, C.R. & Marshall, J.C. (2016) Polycystic ovary syndrome. New England Journal of Medicine, 375, 54–64.
3. Dunaif, A. (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews, 18, 774–800.
4. Tang, T., Lord, J.M., Norman, R.J. et al. (2012) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews, 16, CD003053.
5. Palomba, S., Falbo, A., Zullo, F. et al. (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocrine Reviews, 30, 1–50.
6. Fulghesu, A.M., Romualdi, D., Di Florio, C. et al. (2012) Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study. Human Reproduction, 27, 3057–3066.
7. Azziz, R., Ehrmann, D., Legro, R.S. et al. (2001) Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism, 86, 1626–1632.
8. Romualdi, D., Guido, M., Ciampelli, M. et al. (2003) Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Human Reproduction, 18, 1210–1218.
9. Larner, J. (2002) D-chiro-inositol–its functional role in insulin action and its deficit in insulin resistance. International Journal of Experimental Diabetes Research, 3, 47–60.
10. Chiu, T.T., Rogers, M.S., Law, E.L. et al. (2002) Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Human Reproduction, 17, 1591–1596.
11. Unfer, V., Carlomagno, G., Dante, G. et al. (2012) Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecological Endocrinology, 28, 509–515.
12. Raffone, E., Rizzo, P. & Benedetto, V. (2010) Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecological Endocrinology, 26, 275–280.
13. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. (2003) Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction, 19, 41–47.
14. New, M.I., Lorenzen, F., Lerner, A.J. et al. (1983) Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. Journal of Clinical Endocrinology and Metabolism, 57, 320–326.
15. Taylor, R.W., Keil, D., Gold, E.J. et al. (1998) Body mass index, waist girth, and waist to hip ratio as indexes of total and regional adiposity in women: evaluation using receiver operating characteristic curves. The American Journal of Clinical Nutrition, 67, 44–49.
16. Ferriman, D. & Gallwey, J.D. (1961) Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology and Metabolism, 21, 1440–1447.
17. Ciampelli, M., Leoni, F., Cucinelli, F. et al. (2005) Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. Journal of Clinical Endocrinology and Metabolism, 90, 398–1406.
18. DeFronzo, J.P., Tobin, J.D. & Andrei, R. (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. American Journal of Physiology, 237, E214–E223.
19. Ciampelli, M., Fulghesu, A.M., Cucinelli, F. et al. (1999) Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism, 48, 167–172.
20. Jonard, S. & Dewailly, D. (2004) The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Human Reproduction Update, 10, 107–117.
21. Chen, M.J., Yang, W.S., Chen, C.L. et al. (2008) The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Human Reproduction, 23, 952–957.
22. Teede, H.J., Deeks, A. & Moran, L. (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine, 8, 41.
23. Baillargeon, J.P., Nestler, J.E., Ostlund, R.E. et al. (2008) Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Human Reproduction, 23, 1439–1446.
24. Vrbíková, J., Hill, M., Stárka, L. et al. (2002) Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome. Gynecologic and Obstetric Investigation, 53, 100–104.
25. Ben-Haroush, A., Yogev, Y. & Fisch, B. (2004) Insulin resistance and metformin in polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 115, 125–133.
26. Kowalska, I., Kinalski, M., Straczkowski, M. et al. (2001) Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. European Journal of Endocrinology, 144, 509–515.
27. Romualdi, D., De Cicco, S., Tagliaferri, V. et al. (2011) The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 96, E821–E824.
28. Genazzani, A.D., Lanzoni, C., Ricchieri, F. et al. (2008) Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecological Endocrinology, 24, 139–144.
29. Genazzani, A.D., Prati, A., Santagni, S. et al. (2012) Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecological Endocrinology, 28, 969–973.
30. Checa, M.A., Requena, A., Salvador, C. et al. (2005) Reproductive endocrinology interest group of the spanish society of fertility. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Human Reproduction Update, 1, 375–390.
31. Artini, P.G., Di Berardino, O.M., Papini, F. et al. (2013) Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecological Endocrinology, 29, 375–379.
32. Gargari, B.P., Aghamohammadi, V. & Aliasgharzadeh, A. (2011) Effect of folic acid supplementation on biochemical indices in overweight and obese men with type 2 diabetes. Diabetes Research and Clinical Practice, 94, 33–38.
33. Villa, P., Perri, C., Suriano, R. et al. (2005) L-folic acid supplementation in healthy postmenopausal women: effect on homocysteine and glycolipid metabolism. Journal of Clinical Endocrinology and Metabolism, 90, 4622–4629.
34. Facchinetti, F., Bizzarri, M., Benvenga, S. et al. (2015) Results from the International consensus conference on Myo-inositol and d-chiro-inositol in obstetrics and gynecology: the link between metabolic syndrome and PCOS. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 195, 72–76.
35. Bosi, E. (2009) Metformin–the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes, Obesity & Metabolism, 11(Suppl 2), 3–8.